Curated News
By: NewsRamp Editorial Staff
May 14, 2026

Tonix Pharmaceuticals to Present Real-World Fibromyalgia Data at ISPOR 2026

Discuss on Substack
Original Source

TLDR

  • Tonix's TONMYA gains FDA approval and commercial launch, offering a competitive edge as the first new fibromyalgia treatment in 15 years.
  • Tonix presents real-world data from a retrospective cohort study at ISPOR 2026, analyzing U.S. claims from adults with fibromyalgia.
  • Tonix's new fibromyalgia treatment TONMYA addresses a high unmet medical need, potentially improving quality of life for millions.
  • TONMYA is the first new fibromyalgia drug in over 15 years, and Tonix is exploring its use for depression and stress disorder.

Impact - Why it Matters

This news matters because Tonix's TONMYA is the first new fibromyalgia treatment in over 15 years, offering hope to millions of patients who have had limited therapeutic options. Real-world data from this study could validate TONMYA's effectiveness in everyday clinical settings, potentially influencing prescribing practices and insurance coverage. For investors, positive data may boost confidence in Tonix's commercial strategy and pipeline, including its broader CNS and immunology programs.

Summary

Tonix Pharmaceuticals (NASDAQ: TNXP) is set to present new real-world data on fibromyalgia treatment at the upcoming ISPOR 2026 conference. The poster presentation will highlight findings from a retrospective cohort study analyzing U.S. claims data from adults with fibromyalgia between April 2021 and April 2024. This research comes on the heels of the FDA approval of TONMYA(R) in August 2025 and its U.S. commercial launch in November 2025, marking the first new treatment for fibromyalgia in over 15 years. Tonix Pharmaceuticals, a fully-integrated commercial-stage biotechnology company, focuses on central nervous system (CNS) and immunology treatments in areas of high unmet medical need. TONMYA(TM) (cyclobenzaprine HCl sublingual tablets 2.8mg) is the company's recently approved flagship medicine. The company's CNS commercial infrastructure also supports its acute migraine products, Zembrace(R) SymTouch(R) and Tosymra(R). Tonix is exploring TONMYA's potential in Phase 2 clinical trials for major depressive disorder and acute stress disorder. Additionally, the CNS portfolio includes TNX-2900, which is Phase 2 ready for Prader-Willi syndrome, a rare disease. Tonix is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The presentation at ISPOR 2026 will provide valuable insights into real-world fibromyalgia treatment patterns following the introduction of TONMYA. For more details, the full press release is available at https://ibn.fm/A3668. Investors can stay updated on TNXP news via the company's newsroom at https://ibn.fm/TNXP. This announcement was distributed by TechMediaWire, a specialized communications platform that is part of the Dynamic Brand Portfolio @ IBN. TechMediaWire offers a range of services including press release distribution, editorial syndication to 5,000+ outlets, and social media distribution via IBN. For more information, visit www.TechMediaWire.com.

Source Statement

This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Pharmaceuticals to Present Real-World Fibromyalgia Data at ISPOR 2026

blockchain registration record for this content.